Metraipolis › archive › dc_c670ade0454d

A Phase II Pilot Study of Anti-PD-L1, Durvalumab, and a PARP Inhibitor, Olaparib in Patients With Metastatic Triple-Negative Breast Cancer With or Without… — Europe PMC PMID:41360639

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41360639
DOI
10.1002/cam4.71220
License (as archived)
solo-consultazione
Archived
2026-11-08T03:06:27.004Z
SHA-256 of the archived text
ba3ad91f5064d0b54bcd88a93a9a04a2fff1e4f75910f388de58b4786fc4e318
Stable URL of this page
https://metraipolis.com/documento/dc_c670ade0454d

How to cite

A Phase II Pilot Study of Anti-PD-L1, Durvalumab, and a PARP Inhibitor, Olaparib in Patients With Metastatic Triple-Negative Breast Cancer With or Without… — Europe PMC PMID:41360639 — Europe PMC (en), https://europepmc.org/article/MED/41360639 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_c670ade0454d (Metraipolis archive dc_c670ade0454d, sha256 ba3ad91f5064d0b54bcd88a93a9a04a2fff1e4f75910f388de58b4786fc4e318)
BibTeX
@misc{dcc670ade0454d,
  title = {A Phase II Pilot Study of Anti-PD-L1, Durvalumab, and a PARP Inhibitor, Olaparib in Patients With Metastatic Triple-Negative Breast Cancer With or Without… — Europe PMC PMID:41360639},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41360639},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_c670ade0454d; sha256 ba3ad91f5064d0b54bcd88a93a9a04a2fff1e4f75910f388de58b4786fc4e318},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41360639. Agents can read the archived copy with the MCP tool read_document.